论文部分内容阅读
目的观察异环磷酰胺(IFO)联合表阿霉素(EPI)方案治疗晚期软组织肉瘤(ASTS)的疗效与安全性。方法采用IFO+EPI方案治疗ASTS 27例。IFO 6g/m2,分d1~3静脉滴入或96 h持续静脉点滴;EPI 90 mg/m2,分d1~3(或96 h持续静脉点滴),21 d为1个周期。本组中位化疗周期数为3个(2~5个)。结果CR 0例,PR 5例,SD 13例,PD 9例,全组总有效率18.5%,临床获益率为66.7%,1年生存率为37.0%,2年生存率为11.1%。其中5例PR患者均为一线治疗,一线治疗有效率为23.8%(5/21)。主要毒性反应为骨髓抑制及胃肠道反应。结论EPI联合IFO治疗ASTS,使用方便、疗效确切、毒性反应较轻,该方案是ASTS有效解救治疗方案。
Objective To observe the efficacy and safety of ifosfamide (IFO) combined with epirubicin (EPI) in the treatment of advanced soft tissue sarcoma (ASTS). Methods The treatment of ASTS with IFO + EPI regimen was performed in 27 cases. IFO 6g / m2, d1 ~ 3 intravenous infusion or 96h continuous intravenous drip; EPI 90mg / m2, d1 ~ 3 (or 96h continuous intravenous drip), 21d for a cycle. The median number of cycles of chemotherapy in this group is 3 (2 ~ 5). Results There were 0 cases of CR, 5 cases of PR, 13 cases of SD and 9 cases of PD. The total effective rate was 18.5%. The clinical benefit rate was 66.7%. The 1-year survival rate was 37.0% and the 2-year survival rate was 11.1%. Among them, 5 cases of PR patients were first-line treatment, first-line treatment was 23.8% (5/21). The main toxicity is myelosuppression and gastrointestinal reactions. Conclusion The combination of EPI and IFO in the treatment of ASTS is easy to use, effective and less toxic. This regimen is an effective treatment for ASTS.